Radius Health Inc logo

RDUS - Radius Health Inc News Story

$11.86 -0.2  -1.3%

Last Trade - 3:05pm

Sector
Healthcare
Size
Mid Cap
Market Cap £425.3m
Enterprise Value £480.0m
Revenue £146.0m
Position in Universe 2847th / 6368

BRIEF-Pivotal Phase III Trial Of Abaloparatide-SC In Japanese Women And Men With Osteoporosis Achieves Primary Endpoint

Wed 27th May, 2020 11:07am
May 27 (Reuters) - Radius Health Inc  RDUS.O :
    * PIVOTAL PHASE III TRIAL OF ABALOPARATIDE-SC IN JAPANESE
WOMEN
AND MEN WITH OSTEOPOROSIS ACHIEVES PRIMARY ENDPOINT
    * RADIUS HEALTH - RADIUS PARTNER TEIJIN PHARMA SUBMITTED NEW
DRUG
APPLICATION FOR ABALOPARATIDE-SC FOR TREATMENT OF OSTEOPOROSIS
IN JAPAN
    * RADIUS HEALTH - APPLICATION BASED ON POSITIVE RESULTS OF
PHASE
III CLINICAL STUDY OF ABALOPARATIDE-SC IN JAPAN
    * RADIUS HEALTH - STUDY ACHIEVED EFFICACY ENDPOINT WITH
SIGNIFICANT INCREASE IN LUMBAR SPINE BONE MINERAL DENSITY AT 18
MONTHS

Source text for Eikon:  ID:nGNX44pb2R 
Further company coverage:  RDUS.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.